Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition

The mammalian target of rapamycin (mTOR) has emerged as an important cancer therapeutic target. Rapamycin and its derivatives that specifically inhibit mTOR are now being actively evaluated in clinical trials. Recently, the inhibition of mTOR has been shown to reverse Akt-dependent prostate intraepi...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 65; no. 16; p. 7052
Main Authors:	Sun, Shi-Yong, Rosenberg, Laura M, Wang, Xuerong, Zhou, Zhongmei, Yue, Ping, Fu, Haian, Khuri, Fadlo R
Format:	Journal Article
Language:	English
Published:	United States 15.08.2005
Subjects:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - metabolism Cell Growth Processes - drug effects Cell Line, Tumor Chromones - administration & dosage Enzyme Activation Eukaryotic Initiation Factor-4E - metabolism Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - metabolism Morpholines - administration & dosage Phosphatidylinositol 3-Kinases - metabolism Phosphorylation - drug effects Protein Kinase Inhibitors - pharmacology Protein Kinases - metabolism Protein-Serine-Threonine Kinases - metabolism Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins c-akt Ribosomal Protein S6 Kinases, 70-kDa - metabolism Signal Transduction - drug effects Sirolimus - administration & dosage Sirolimus - pharmacology TOR Serine-Threonine Kinases
ISSN:	0008-5472
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!